Study guide
Section 6.3: Schizophrenia and Psychotic Disorders
NCCPA PANCE Physician Assistant Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular System
1.1 Hypertension (Essential & Secondary) 1.2 Coronary Artery Disease & Myocardial Infarction 1.3 Heart Failure & Cardiomyopathy 1.4 Cardiac Arrhythmias & Conduction Disorders 1.5 Valvular Heart Disease 1.6 Vascular Diseases (Aortic Aneurysm, PAD, DVT) 1.7 Congenital Heart Disease (ASD, VSD, PDA, Coarctation, Tetralogy of Fallot)
2 Chapter 2: Pulmonary System
Section 2.1: Asthma & Bronchospastic Disease Section 2.2: Chronic Obstructive Pulmonary Disease (COPD) Section 2.3: Infectious Pulmonary Disorders (Pneumonia & Tuberculosis) Section 2.4: Restrictive, Vascular & Neoplastic Pulmonary Conditions
3 Chapter 3: Gastrointestinal/Nutrition
3.1 Esophageal & Gastric Disorders (GERD, PUD) 3.2 Hepatic, Biliary & Pancreatic Disorders 3.3 Small & Large Bowel Disorders (IBD, Diverticulitis, Obstruction) 3.4 Colorectal Neoplasms & Nutritional Deficiencies
4 Chapter 4: Musculoskeletal System
Section 4.1: Rheumatologic & Autoimmune MSK Conditions (RA, Lupus, Gout, OA) Section 4.2: Infectious & Inflammatory MSK Disorders (Osteomyelitis, Septic Arthritis) Section 4.3: Bone & Joint Disorders (Fractures, Osteoporosis, Fibromyalgia) Section 4.4: Spine and Soft Tissue Pathology (Low Back Pain, Tendonitis)
5 Chapter 5: Neurologic System
Section 5.1: Cerebrovascular Disease (Stroke, TIA) Section 5.2: Seizure Disorders & Epilepsy Section 5.3: Demyelinating & Neurodegenerative Diseases Section 5.4: Headache Syndromes & Cranial Nerve Disorders
6 Chapter 6: Psychiatry/Behavioral Science
Section 6.1: Depressive and Bipolar Disorders Section 6.2: Anxiety, Trauma-Related, and Obsessive-Compulsive Disorders Section 6.3: Schizophrenia and Psychotic Disorders Section 6.4: Eating, Substance Use, and Personality Disorders
7 Chapter 7: Infectious Diseases
7.1 Viral Infections (HIV, EBV, Influenza) 7.2 Bacterial & Spirochetal Infections (Sepsis, Meningitis) 7.3 Fungal & Parasitic Infections 7.4 Tick-Borne Diseases (Lyme, Rocky Mountain Spotted Fever)
8 Chapter 8: Reproductive System
8.1 Obstetrics: Normal Pregnancy & Prenatal Care 8.2 Obstetrics: Pregnancy Complications 8.3 Gynecology: Menstruation, Menopause, PCOS, and Vaginal Infections
9 Chapter 9: Endocrine System
Section 9.1: Diabetes Mellitus & Acute Complications Section 9.2: Thyroid Disorders & Goiter Section 9.3: Adrenal & Pituitary Disorders
10 Chapter 10: Eyes, Ears, Nose, and Throat
Section 10.1: Ophthalmic Disorders (Glaucoma, Conjunctivitis, Cataracts) Section 10.2: Otic Disorders (Otitis Media/Externa, Vertigo, Labyrinthitis) Section 10.3: Nose, Sinus, and Throat Complaints (Sinusitis, Pharyngitis, Epiglottitis)
11 Chapter 11: Professional Practice
11.1 Bioethics & Legal Standards (Informed Consent, Autonomy, HIPAA) 11.2 Patient Safety, Quality Improvement, and Communication 11.3 Evidence-Based Medicine & Clinical Practice Guidelines
12 Chapter 12: Hematologic System
Section 12.1: Anemias (Microcytic, Macrocytic, Hemolytic/Sickle Cell) Section 12.2: Coagulation and Bleeding Disorders (ITP, TTP, Hemophilia, vWD) Section 12.3: Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
13 Chapter 13: Renal System
13.1 Acute Kidney Injury (AKI) & Chronic Kidney Disease (CKD) 13.2 Acid-Base and Electrolyte Disorders 13.3 Glomerular & Tubulointerstitial Diseases
14 Chapter 14: Dermatologic System
Section 14.1: Inflammatory & Autoimmune Skin Conditions Section 14.2: Infectious Skin Conditions Section 14.3: Skin Neoplasms & Burn Management
15 Chapter 15: Genitourinary System
Section 15.1: Male Genitourinary Disorders (BPH, Prostate Cancer, Testicular Torsion, ED) Section 15.2: Urinary Incontinence, Nephrolithiasis, and GU Trauma
Section 6.3: Schizophrenia and Psychotic Disorders
Key Takeaways Explain This Topic AI
Schizophrenia requires symptoms to persist for at least 6 months; symptoms lasting 1-6 months are diagnosed as Schizophreniform Disorder.
Positive symptoms are linked to mesolimbic dopamine excess; negative symptoms are linked to mesocortical dopamine deficiency.
First-generation antipsychotics carry high EPS risk; second-generation agents carry high metabolic risk (weight gain, dyslipidemia).
Clozapine is reserved for treatment-resistant schizophrenia and requires strict monitoring of the Absolute Neutrophil Count (ANC) due to agranulocytosis risk.
Neuroleptic Malignant Syndrome (NMS) presents with fever, autonomic instability, and lead-pipe rigidity; treat with dantrolene or bromocriptine.
Last updated: July 2026
Why Schizophrenia and Psychotic Disorders Matter for the PANCE
Psychotic disorders carry significant clinical morbidity, and their diagnostic criteria, classification timelines, and pharmacotherapy side effects are heavily tested on the PANCE. Candidates must be proficient in distinguishing psychotic disorders based on duration (Brief Psychotic Disorder vs. Schizophreniform vs. Schizophrenia), separating positive from negative symptoms, and managing critical antipsychotic-related adverse events. Specifically, life-threatening emergencies like Neuroleptic Malignant Syndrome (NMS) and highly distressing Extrapyramidal Symptoms (EPS) require rapid clinical recognition and intervention.
- Schizophrenia
- Pathophysiology
The primary pathophysiology of schizophrenia involves dysregulation of dopamine pathways:
Mesolimbic Pathway : Excess dopamine activity is responsible for the positive symptoms (hallucinations, delusions).
Mesocortical Pathway : Dopamine deficiency is responsible for the negative symptoms (flat affect, avolition, alogia) and cognitive deficits.
Nigrostriatal Pathway : Antipsychotic D2 blockade in this pathway leads to Extrapyramidal Symptoms (EPS) .
Tuberoinfundibular Pathway : Antipsychotic D2 blockade here blocks dopamine's tonic inhibition of prolactin, leading to hyperprolactinemia (galactorrhea, gynecomastia, sexual dysfunction).
Diagnostic Criteria and Timeline
According to the DSM-5-TR, a patient must present with two or more of the following symptoms for a significant portion of time during a 1-month period (active-phase), and continuous signs of the disturbance must persist for at least 6 months :
Delusions (fixed, false beliefs, e.g., persecutory, grandiose, ideas of reference).
Hallucinations (sensory perceptions without external stimuli; auditory is most common).
Disorganized speech (e.g., frequent derailment, loose associations, incoherence or 'word salad').
Grossly disorganized or catatonic behavior .
Negative symptoms .
At least one of the symptoms must be delusions, hallucinations, or disorganized speech.
PANCE Timeline Trap : The diagnosis of psychotic disorders is strictly tied to the duration of symptoms:
Brief Psychotic Disorder : Symptoms last less than 1 month with a full return to premorbid functioning.
Schizophreniform Disorder : Symptoms last between 1 and 6 months .
Schizophrenia : Symptoms last greater than 6 months and cause significant social or occupational dysfunction.
Schizoaffective Disorder : Characterized by an uninterrupted period of illness during which there is a major mood episode (depressive or manic) concurrent with symptoms of schizophrenia, alongside at least 2 weeks of delusions or hallucinations in the absence of a major mood episode .
Positive vs. Negative Symptoms
Positive Symptoms (added behaviors): Delusions, hallucinations, disorganized speech, bizarre behavior.
Negative Symptoms (subtracted behaviors - 'The A's'):
Flat Affect : Lack of emotional expression.
Avolition : Lack of motivation or goal-directed behavior.
Alogia : Poverty of speech.
Anhedonia : Inability to experience pleasure.
Asociality : Social withdrawal.
Antipsychotic Pharmacotherapy
Antipsychotics are divided into first-generation (typical) and second-generation (atypical) agents.
First-Generation Antipsychotics (FGAs)
Examples include Haloperidol , Fluphenazine , and Chlorpromazine .
Mechanism : High-potency dopamine D2 receptor antagonists.
Target : Highly effective against positive symptoms, but poor efficacy for negative symptoms.
Adverse Effects : High rates of EPS, hyperprolactinemia, and QT prolongation. Chlorpromazine (low-potency) is associated with corneal deposits, while Thioridazine is associated with irreversible retinitis pigmentosa.
Second-Generation Antipsychotics (SGAs)
Examples include Risperidone , Olanzapine , Quetiapine , Aripiprazole , Ziprasidone , and Clozapine .
Mechanism : Dopamine D2 and Serotonin (5-HT2A) receptor antagonists.
Target : Treat both positive and negative symptoms with a lower risk of EPS.
Adverse Effects : High risk of metabolic syndrome (dyslipidemia, weight gain, hyperglycemia). Olanzapine and clozapine carry the highest metabolic risk. Ziprasidone carries a high risk of QT prolongation but has minimal metabolic side effects. Aripiprazole is a D2 partial agonist and is weight-neutral. Risperidone is notorious for causing significant hyperprolactinemia.
Clozapine: A High-Yield Exception
Clozapine is the most effective antipsychotic but is reserved for treatment-resistant schizophrenia (failure of two prior trials of different antipsychotics) due to its severe side effects.
Agranulocytosis : Clozapine can cause life-threatening neutropenia. Patients must be enrolled in the Clozapine REMS program, requiring regular Absolute Neutrophil Count (ANC) monitoring (weekly for the first 6 months, biweekly for the next 6 months, then monthly). Treatment must be interrupted if the ANC falls below 1,500/mcL.
Other Adverse Effects : Severe myocarditis, cardiomyopathy, seizures (lowers seizure threshold), and sialorrhea (excessive drooling).
Antipsychotic-Induced Movement Disorders (EPS)
EPS results from dopamine D2 receptor blockade in the nigrostriatal pathway.
Acute Dystonia :
Timeline : Occurs within hours to days of initiation or dose escalation.
Presentation : Sudden, painful, involuntary muscle spasms, most commonly involving the neck (torticollis), eyes (oculogyric crisis), or tongue.
Management : Intravenous or intramuscular benztropine (anticholinergic) or diphenhydramine .
Akathisia :
Timeline : Occurs within days to weeks .
Presentation : Intense subjective feeling of motor restlessness. The patient is unable to sit still, paces constantly, and is highly distressed.
Management : Beta-blockers (Propranolol) are first-line. Benzodiazepines (lorazepam) or dose reduction can also be used.
Drug-Induced Parkinsonism :
Timeline : Occurs within weeks to months .
Presentation : Bradykinesia, rigidity (cogwheel), resting tremor, masked facies, and shuffling gait.
Management : Benztropine or amantadine (a dopamine agonist that does not worsen psychosis).
Tardive Dyskinesia (TD) :
Timeline : Occurs after months to years of long-term use.
Presentation : Involuntary, choreoathetoid movements of the face, mouth, and tongue (lip-smacking, tongue protrusion, puckering), and sometimes extremities. Caused by D2 receptor upregulation and supersensitivity.
Management : Discontinue or reduce the dose of the current drug, or switch to a lower-risk atypical (clozapine or quetiapine). Valbenazine or deutetrabenazine (VMAT2 inhibitors) are FDA-approved treatments. Anticholinergics (benztropine) are contraindicated as they worsen tardive dyskinesia.
Neuroleptic Malignant Syndrome (NMS)
NMS is a life-threatening, idiosyncratic reaction to dopamine antagonists (mostly antipsychotics).
Clinical Presentation
Can be remembered with the mnemonic FEVER :
F ever: Severe hyperthermia (often >104°F or 40°C).
E ncephalopathy: Altered mental status, delirium, agitation, stupor.
V itals unstable: Autonomic instability (tachycardia, tachypnea, labile blood pressure, diaphoresis).
E levated enzymes: Markedly elevated creatine kinase (CK) (often >10,000 U/L due to muscle breakdown), leukocytosis, and transaminases.
R igidity: Generalized, severe 'lead-pipe' muscle rigidity .
Management
Immediate Action : Discontinue the offending antipsychotic immediately.
Supportive Care : ICU admission, aggressive cooling (cooling blankets, ice packs), IV fluids (to maintain urine output and prevent acute kidney injury from rhabdomyolysis), and correction of electrolyte abnormalities.
Pharmacotherapy :
Dantrolene : A direct-acting skeletal muscle relaxant to reduce hyperthermia and rigidity.
Bromocriptine : A dopamine agonist to overcome the severe dopamine blockade.
Condition Primary Mechanism Characteristic Presentation First-Line Management
Acute Dystonia Nigrostriatal D2 blockade Muscle spasms (torticollis, oculogyric crisis) IV/IM Benztropine or Diphenhydramine
Akathisia Nigrostriatal D2 blockade Subjective/objective restlessness Propranolol (Beta-blocker)
Tardive Dyskinesia D2 receptor upregulation Lip-smacking, tongue protrusion VMAT2 inhibitors (Valbenazine); switch to Clozapine
NMS Severe hypothalamic/striatal D2 blockade 'Lead-pipe' rigidity, hyperthermia, high CK Stop drug; Supportive care, Dantrolene, Bromocriptine
Classic PANCE Traps & Clinical Pearls
The Benztropine Tardive Dyskinesia Trap : A common PANCE trap presents a patient with chronic schizophrenia who has developed lip-smacking after 5 years on haloperidol. The question will ask for management. Adding benztropine is a trap; it will worsen tardive dyskinesia. The correct action is to taper the drug and switch to an atypical like clozapine or quetiapine, or start a VMAT2 inhibitor.
NMS vs. Serotonin Syndrome Rigidity : Both cause hyperthermia and autonomic instability. However, NMS presents with 'lead-pipe' rigidity and bradyreflexia, whereas Serotonin Syndrome presents with hyperreflexia and clonus . Additionally, NMS is triggered by dopamine antagonists (antipsychotics), while Serotonin Syndrome is triggered by serotonergic agents (SSRIs, SNRIs).
Clozapine Monitoring : ANC is the parameter to watch, not total white blood cell count (WBC), although WBC is related. The registry tracks ANC specifically. Agranulocytosis refers to a severe deficiency of granulocytes (neutrophils).